From: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Study | Participants | Intervention | Duration (weeks) | Difference amongst groups (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
△HbA1c (%) | △FPG (mmol/L) | △SBP (mmHg) | △Body weight (kg) | △eGFR (mL/min/1.73 m2) | △UACR | △Serum uric acid (μmol/L) | △Albuminuria | ||||
Heerspink [49] | A: n = 167 B: n = 189 | A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO | 12 | A–B: −0.5% (−0.7, −0.3) | NR | A–B: −3.5 (−5.9, −1.0) | A − B: −0.76 (−1.27, −0.26) | A–B: −2.80 (−5.43, −0.16) | A–B: −23.5% (−37.6, −6.3) | NR | A–B: −33.2% (−45.4, −18.2) |
Weber [50] | A: n = 302 B: n = 311 | A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO | 12 | A–B: −0.49 (−0.59, −0.33) | A–B: (−0.69 vs 0.38) | A–B: −3.1 (−4.9, −1.2) | A–B: (−1.0 vs −0.3) | NS | NR | A–B: (−17.84 vs 5.95) | NR |
Weber [51] | A: n = 225 B: n = 224 | A: DAPA 10 mg + ACEI/ARB B: ACEI/ARB + PBO | 12 | A–B: −0.61% (−0.76, −0.46) | A–B: −1.2 (−1.7, −0.8) | A–B: −4.28 (−6.54, −2.02) | A–B: −0·85 (−1.39, −0.31) | NS | NS | A–B: −23.67 (−33.70, −13.64) | NR |
Sha [52] | A: n = 18 B: n = 18 | A: CANA 300 mg + ACEI/ARB + MET B: ACEI/ARB + PBO + MET | 12 | A–B: −0.6% (−0.9, −0.3) | A–B: −1.6 (−2.3, −0.9) | A–B: −13.3 (−21.2, −5.3) (supine SBP) A–B: −16.2 (−24.9, −7.5) (standing SBP) | A–B: −3.5 (−4.2, −2.7) | A–B: −4.0 (−8.7, 0.7) | NR | NR | NR |